Skip to main content
. 2022 Sep 21;11(19):5527. doi: 10.3390/jcm11195527

Table 1.

Demographic Characteristics. On the LEFT, patients are classified in cardioverted vs. non-cardioverted; on the RIGHT patients are classified in MgSO4 infused v.sv. MgSO4 non-infused.

p-Value 14 Non-Cardioverted pts (14.4%) 83 Cardioverted pts (85.6%) Variables MgSO4 Infusion
(46 pts)
No MgSO4 Infusion
(51 pts)
p-Value
- - - Cardioverted pts 42 (91.3%) 41 (80.4%) p = 0.98
- - 27 (32.5%) Cardioverted before Flecainide infusion 18 (39.1%) 9 (17.6%) p= 0.018
p = 0.43 9 (64.3%) 44 (53%) Gender (Male) 29 (63%) 24 (47.1%) p > 0.05
p = 0.59 64.7 (±12.1) 66.5 (±10.9) Age 64.4 (±11.9) 67.9 (±10.1) p = 0.99
p = 0.51 127.6 (±18.6) 121.9 (±23.9) HR at arrival (bpm) 128.5 (±23.8) 129.1 (±23.2) p = 0.99
p < 0.01 123.1 (±13.8) after 6 h 75.7 (±12.2) HR at cardioversion (bpm) 77.8 (±19.1) 87 (±21.7) p= 0.026
p = 0.37 2.1 (±0.2) 2.1 (±0.1) Mg pre-Mg (mmol/L) 2.1 (±0.2) 2.1 (±0.1) p = 0.87
- - 2.8 (±0.3) Mg post-Mg (mmol/L) 2.8 (±0.4) -
p = 0.32 4 (±0.4) 3.9 (±0.4) K pre-Mg (mmol/L) 3.9 (±0.4) 3.9 (±0.4) p = 0.93
- - 4 (±0.5) K post-Mg (mmol/L) 4 (±0.5) -
p < 0.01 2573.6 (±2972.4) 626.6 (±714.4) NT-proBNP on arrival (pg/mL) 971 (±1559.7) 665 (±644) p = 0.98
p = 0.95 5 (35.7%) 29 (34.9%) First AF episode 20 (43.4%) 14 (27.4%) p = 0.09
p = 0.65 5 (35.7%) 37 (44.6%) Paroxysmal AF 19 (41.3%) 23 (45.1%) p = 0.89
p = 0.68 1 (7.1%) 12 (14.5%) Diuretics drugs 6 (13%) 7 (13.7%) p = 0.92
p = 1 0 2 (2.4%) K-sparing diuretics 2 (4.3%) 0 p = 0.22
p = 0.751 3 (21.4%) 25 (30.1%) Beta Blockers 16 (34.7%) 12 (23.5%) p = 0.22
p = 0.59 2 (14.3%) 8 (9.6%) Calcium channel blockers 2 (4.4%) 8 (15.6%) p = 0.09
p = 0.83 3 (21.4%) 20 (24.1%) Flecainide 8 (17.4%) 15 (29.4%) p = 0.16
p = 1 0 3 (3.6%) Propafenone 2 (4.3%) 1 (1.9%) p = 0.49
- 0 0 Digoxin 0 0 -
p = 1 0 1 (1.2%) Amiodarone 1 (2.1%) 0 p = 0.47
p = 0.63 2 (14.3%) 8 (9.6%) PPI 7 (15.2%) 3 (5.8%) p = 0.13